🇺🇸 FDA

Intelligence · Clinical Pipeline

Infectious disease · Phase II

Infectious disease programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
375

Quick answer

Infectious disease Phase II programs: NovaPharmaNews indexes 375 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 5 of 8

  1. Merimepodib

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  2. Meropenem-Vaborbactam

    Lacuna Pharma Pty Ltd

    Complicated Urinary Tract Infection (cUTI), Acute Pyelonephritis (AP)

    phase 2 small molecule active

    1 trial

  3. Metronidazole

    Teva Pharma GmbH

    Bacterial Vaginosis

    phase 2 small molecule completed

    1 trial

  4. Metronidazole 500 mg / 100 ml Intravenous Infusion, Metronidazole 500mg/100ml Solution for Infusion, Aztreonam and Avibactam (1.5g/0.5g) Powder for Concentrate for Solution for Infusion, Metronidazole

    Pfizer Australia Pty Ltd

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    phase 2 small molecule active

    1 trial

  5. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

  6. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  7. Motavizumab, palivizumab

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 mab completed

    1 trial

  8. Multimedia WORTH

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  9. NOV-205

    Cellectar Biosciences

    Hepatitis C

    phase 2 small molecule completed

    2 trials

  10. NS2

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 2 small molecule completed

    1 trial

  11. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  12. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  13. NestaCell®

    Vera Therapeutics

    COVID-19 Pneumonia

    phase 2 mab completed

    1 trial

  14. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  15. Norovirus Bivalent Vaccine

    Takeda

    Prevention From Norovirus Infection

    phase 2 mab completed

    1 trial

  16. Noxafil 300 mg concentrate for solution for infusion, Posaconazole, Posaconazole

    Merck Sharp and Dohme

    Fungal infection

    phase 2 small molecule active

    1 trial

  17. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  18. OT-101

    Oncotelic Therapeutics

    COVID-19

    phase 2 small molecule active

    1 trial

  19. OZ439

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  20. Olorofim

    Biotech Pharmaceutical Co.,

    Invasive Fungal Infections

    phase 2 small molecule completed

    1 trial

  21. Opaganib

    RedHill Biopharma

    Coronavirus Infections

    phase 2 small molecule completed

    1 trial

  22. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial

  23. Oral Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  24. PALONOSETRON, FAMOTIDINE, DEXAMETHASONE PHOSPHATE, Plitidepsin, DEXCHLORPHENIRAMINE, PLACEBO

    MEDA Pharma GmbH & Co. KG

    post-COVID-19 Condition (PCC)

    phase 2 small molecule active

    1 trial

  25. PEG-IFNα

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  26. PENNVAX-GP

    INOVIO PHARMACEUTICALS, INC.

    HIV-1-infection

    phase 2 mab completed

    1 trial

  27. PUL-042 Inhalation Solution

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 small molecule completed

    2 trials

  28. PYRIMETHAMINE, LENALIDOMIDE, PANOBINOSTAT

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  29. Part1:Recombinant two-component COVID-19 vaccine (CHO cell)

    Jian Li

    COVID-19

    phase 2 mab completed

    1 trial

  30. Pegasys 180 micrograms solution for injection in pre-filled syringe, VIR-3434, Viread 245 mg film-coated tablets, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis B Virus (HBV) Infection

    phase 2 small molecule active

    1 trial

  31. Phage Therapy

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 mab terminated

    2 trials

  32. Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with MPSIIIA.

    Esteve Pharmaceuticals

    Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)

    phase 2 other active

    1 trial

  33. Piclidenoson

    Can-Fite BioPharma

    COVID-19

    phase 2 small molecule completed

    1 trial

  34. Placebo

    Spero Therapeutics

    Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

    phase 2 small molecule completed

    1 trial

  35. Placebo

    Lacuna Pharma Pty Ltd

    Severe Alcohol-Associated Hepatitis

    phase 2 small molecule active

    1 trial

  36. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  37. Placebo for AZD2693 Solution for Injection, Placebo for AZD2693 Solution for Injection

    AstraZeneca AB

    Non-cirrhotic non-alcoholic steatohepatitis with fibrosis

    phase 2 small molecule active

    1 trial

  38. Placebo for AZD4144, AZD4144

    AstraZeneca AB

    Sepsis-associated acute kidney injury (AKI)

    phase 2 small molecule active

    1 trial

  39. Placebo for AZD5148, AZD5148

    AstraZeneca AB

    Recurrence of Clostridioides difficile Infection

    phase 2 small molecule active

    1 trial

  40. Placebo for Bepirovirsen Solution for Injection, 150 mg/mL SSD

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  41. Placebo for GSK3739937 Tablets are tablets for oral administration and visually match the active GSK3739937 Tablets with the omission of the active ingredient. Placebo for GSK3739937 Tablets are white, round, film coated tablets containing no markings.

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  42. Placebo to ISL, Placebo to MK-8507, Placebo to BIC/FTC/TAF, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, islatravir, ulonivirine

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  43. Placebo to Match GSK3965193 Tablets

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  44. PvCS/Montanide ISA-51 VG Vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Plasmodium Vivax Malaria

    phase 2 mab active

    1 trial

  45. REC-3964

    RECURSION PHARMACEUTICALS, INC.

    Recurrent Clostridioides Difficile Infection

    phase 2 small molecule terminated

    1 trial

  46. REGN10933+REGN10987 combination therapy

    Regeneron UK Limited

    COVID-19

    phase 2 small molecule completed

    2 trials

  47. REGN7041

    Regeneron UK Limited

    Active Noninfectious Uveitis Affecting the Posterior Segment

    phase 2 small molecule active

    1 trial

  48. REGN7041

    Lacuna Pharma Pty Ltd

    Noninfectious Uveitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many infectious disease Phase II programs exist?

375 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.